325 related articles for article (PubMed ID: 15955393)
1. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.
Abraham J; Davis C
Soc Sci Med; 2005 Sep; 61(5):881-92. PubMed ID: 15955393
[TBL] [Abstract][Full Text] [Related]
2. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
3. Unapproved drugs in the United States and the Food and Drug Administration.
Nasr A; Lauterio TJ; Davis MW
Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
[TBL] [Abstract][Full Text] [Related]
4. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
5. We really need to talk: adapting FDA processes to rapid change.
Lykken S
Food Drug Law J; 2013; 68(4):357-99, i. PubMed ID: 24552079
[TBL] [Abstract][Full Text] [Related]
6. International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts.
Abraham J; Davis C
Soc Sci Med; 2020 Jun; 255():113005. PubMed ID: 32361122
[TBL] [Abstract][Full Text] [Related]
7. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
8. Drug evaluation and the permissive principle: continuities and contradictions between standards and practices in antidepressant regulation.
Abraham J; Davis C
Soc Stud Sci; 2009 Aug; 39(4):569-98. PubMed ID: 19848109
[TBL] [Abstract][Full Text] [Related]
9. Drug-review deadlines and safety problems.
Carpenter D; Zucker EJ; Avorn J
N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
[TBL] [Abstract][Full Text] [Related]
10. Preventing postmarketing changes in recommended doses and marketing withdrawals.
Peck C
Ernst Schering Res Found Workshop; 2007; (59):209-16. PubMed ID: 17117726
[TBL] [Abstract][Full Text] [Related]
11. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Doua JY; Van Geertruyden JP
Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
[TBL] [Abstract][Full Text] [Related]
12. The complications of controlling agency time discretion: FDA review deadlines and postmarket drug safety.
Carpenter D; Chattopadhyay J; Moffitt S; Nall C
Am J Pol Sci; 2012; 56(1):98-114. PubMed ID: 22400144
[TBL] [Abstract][Full Text] [Related]
13. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
14. Food and Drug Administration Drug Approval Process: A History and Overview.
Williams CT
Nurs Clin North Am; 2016 Mar; 51(1):1-11. PubMed ID: 26897420
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence: the regulatory career of a pharmaceutical concept.
Carpenter D; Tobbell DA
Bull Hist Med; 2011; 85(1):93-131. PubMed ID: 21551918
[TBL] [Abstract][Full Text] [Related]
16. Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval?
Abraham J; Lewis G
Soc Sci Med; 1999 Jun; 48(11):1655-67. PubMed ID: 10400264
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
Vilhelmsson A; Davis C; Mulinari S
PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
[TBL] [Abstract][Full Text] [Related]
18. Data Integrity: History, Issues, and Remediation of Issues.
Rattan AK
PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency.
Herder M
Milbank Q; 2019 Sep; 97(3):820-857. PubMed ID: 31407412
[TBL] [Abstract][Full Text] [Related]
20. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
Rawson NS
CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
